Production (Stage)
Firefly Neuroscience, Inc.
AIFF
$3.46
$0.102.98%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 258.33% | 178.95% | 43.48% | -97.78% | 140.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 258.33% | 178.95% | 43.48% | -97.78% | 140.00% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 258.33% | 178.95% | 43.48% | -97.78% | 140.00% |
| SG&A Expenses | 120.64% | 39.88% | 1,131.29% | 61.23% | 89.30% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 91.12% | 64.88% | 541.94% | 65.02% | 100.18% |
| Operating Income | -89.28% | -63.50% | -559.66% | -295.91% | -99.82% |
| Income Before Tax | -1,052.41% | -251.58% | -559.85% | -291.33% | -105.12% |
| Income Tax Expenses | -- | 100.00% | -- | -- | -- |
| Earnings from Continuing Operations | -1,052.41% | -251.44% | -559.85% | -291.33% | -105.12% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1,052.41% | -251.44% | -559.85% | -291.33% | -105.12% |
| EBIT | -89.28% | -63.50% | -559.66% | -295.91% | -99.82% |
| EBITDA | -- | -63.61% | -562.63% | -299.68% | -- |
| EPS Basic | -706.25% | -48.73% | -242.78% | -175.00% | -615.23% |
| Normalized Basic EPS | -501.19% | -13.91% | -242.93% | -177.19% | -614.29% |
| EPS Diluted | -706.25% | -48.73% | -242.78% | -175.00% | -615.23% |
| Normalized Diluted EPS | -501.19% | -13.91% | -242.93% | -177.19% | -614.29% |
| Average Basic Shares Outstanding | 91.67% | 136.27% | 92.47% | 41.59% | -71.30% |
| Average Diluted Shares Outstanding | 91.67% | 136.27% | 92.47% | 41.59% | -71.30% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |